AlphaYou
Overview
8 funds hold it, insiders have been net buying, and 1 straight earnings beat.
Key stats
Sep 7- Open
- $108.11
- 52-wk high
- $134.38
- High
- $110.01
- 52-wk low
- $81.39
- Low
- $107.36
- Prev close
- $108.79
- Mkt cap
- $187.45B
- P/E
- 35.1x
- Volume
- 7.03M
- Fwd P/E
- 17.9x
- Beta
- 0.59
- Div yield
- 2.28%
- P/S
- 4.0x
- P/B
- 3.7x
- Profit margin
- +11.7%
- Op margin
- +14.7%
- ROE
- +10.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 2.3% above what analysts expected.
Earnings per share
$1.28 expected
Revenue
No comparable estimate
Reports Oct 14, 2026, in 37 days
EPS expected
$1.41 to $1.44
Revenue expected
24 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $11.14B | $11.37B | $11.46B | $11.16B |
| Cost of what it sold | $4.85B | $5.03B | $4.92B | $4.88B |
| Gross profit | $6.29B | $6.34B | $6.54B | $6.28B |
| What it spent | ||||
| Research and development | $732.0M | $785.0M | $735.0M | $756.0M |
| Sales and admin | $3.09B | $3.05B | $3.13B | $3.74B |
| Other operating costs | $414.0M | $472.0M | $422.0M | -$55.0M |
| Total operating expenses | $4.24B | $4.31B | $4.29B | $4.44B |
| What was left | ||||
| Operating profit | $2.05B | $2.06B | $2.25B | $1.84B |
| Interest on debt | $121.0M | $44.0M | $120.0M | $174.0M |
| Profit before tax | $2.15B | $2.18B | $2.36B | $1.45B |
| Tax | $371.0M | $536.0M | $582.0M | $372.0M |
| Net profit | $1.78B | $1.64B | $1.78B | $1.08B |
| EBITDA | $3.05B | $3.09B | $2.82B | $2.25B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
Tone of tracked coverage
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026
NeutralSep 4People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics
NeutralSep 3Abbott ablation device effective at 1 year in complex cases
BullishSep 2Oncology firm Novocure says cyberattack exposed US patient records
Leans bearishSep 1Nifty Pharma Today: Down 1.45% at Close
Leans bullishSep 1Duncan Ferguson joins Neovii Pharmaceuticals AG to lead global commercial expansion as Chief Commercial Officer - boerse.de
NeutralSep 1Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
Leans bearishAug 31ShinyHunters Claims Theft of 284M Records from Healthcare Giant McKesson
Leans bearishAug 31
Macro
30 macro signals shaping ABT right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results